NCT06291935View on ClinicalTrials.gov

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Retinitis Pigmentosa
Interventions
DRUG

VG901

"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"

Trial Locations (1)

72076

RECRUITING

Center for Ophthalmology, University of Tuebingen, Tübingen

All Listed Sponsors
lead

VeonGen Therapeutics GmbH

INDUSTRY